Source:http://linkedlifedata.com/resource/pubmed/id/16166793
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1-2
|
| pubmed:dateCreated |
2005-9-16
|
| pubmed:abstractText |
Etiologic variations of hepatocellular carcinoma (HCC) exist in different geographic areas of the world. Hepatitis B virus infection is associated with HCC. However, hepatitis C virus (HCV) infection plays an increasingly more important role in the development of HCC and is associated with more than 30% of HCC in Taiwan. The prevalence of HCV infection and HCV genotypes vary in different geographic areas. The prevalence of HCV genotype 1b (HCV-1b) was around 50-70% in Taiwan and even varied in different townships. In addition to host factors, HCV genotypes may be associated with the development of HCC. In our study, the prevalence of HCV-1b in patients with HCC was significantly higher than in those with liver cirrhosis and chronic hepatitis; multivariate analysis revealed that the disease severity was significantly correlated with age and HCV-1b. Furthermore, HCV-1b was associated with a lower response rate to interferon (IFN) therapy than HCV-2. Our study has demonstrated that mutations in the IFN sensitivity-determining region, spanning nucleotides 2,209-2,248 in the NS5A region, correlate with the sustained virological response to combination therapy with IFN and ribavirin in patients with chronic HCV-1b infection in Taiwan. A third-generation enzyme immunoassay for antibody to HCV can be used to predict viremia and monitor the virological response.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antiviral Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis C Antibodies,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/NS-5 protein, hepatitis C virus,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Ribavirin,
http://linkedlifedata.com/resource/pubmed/chemical/Viral Nonstructural Proteins
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0300-5526
|
| pubmed:author | |
| pubmed:copyrightInfo |
Copyright (c) 2006 S. Karger AG, Basel.
|
| pubmed:issnType |
Print
|
| pubmed:volume |
49
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
76-81
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:16166793-Age Factors,
pubmed-meshheading:16166793-Antiviral Agents,
pubmed-meshheading:16166793-Biological Markers,
pubmed-meshheading:16166793-Carcinoma, Hepatocellular,
pubmed-meshheading:16166793-Drug Therapy, Combination,
pubmed-meshheading:16166793-Hepacivirus,
pubmed-meshheading:16166793-Hepatitis C, Chronic,
pubmed-meshheading:16166793-Hepatitis C Antibodies,
pubmed-meshheading:16166793-Humans,
pubmed-meshheading:16166793-Interferon-alpha,
pubmed-meshheading:16166793-Liver Neoplasms,
pubmed-meshheading:16166793-Multivariate Analysis,
pubmed-meshheading:16166793-Mutation,
pubmed-meshheading:16166793-RNA, Viral,
pubmed-meshheading:16166793-Ribavirin,
pubmed-meshheading:16166793-Species Specificity,
pubmed-meshheading:16166793-Taiwan,
pubmed-meshheading:16166793-Treatment Outcome,
pubmed-meshheading:16166793-Viral Nonstructural Proteins,
pubmed-meshheading:16166793-Viremia
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
Viral etiology of hepatocellular carcinoma and HCV genotypes in Taiwan.
|
| pubmed:affiliation |
Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, 123 Ta Pei Road, Kaohsiung, Taiwan (ROC). chmolee@ms15.hinet.net
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Review,
Research Support, Non-U.S. Gov't
|